Home / TRAIL/TNFSF10 / Human TRAIL/TNFSF10 Antibody

Human TRAIL/TNFSF10 Antibody

Catalog #: MAB375
21 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB375-SP
MAB375-500
MAB375-100
Cytotoxicity Induced by TRAIL/TNFSF10 and Neutralization by Human TRAIL/TNFSF10 Antibody.
1 Image
Product Details
Citations (21)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRAIL/TNFSF10 Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL/TNFSF10 in direct ELISAs.
Source
Monoclonal Mouse IgG1 Clone # 75411
Purification
Protein A or G purified from ascites
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL/TNFSF10
Thr95-Gly281
Accession # P50591
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Immunohistochemistry
8-25 µg/mL
Immersion fixed paraffin-embedded sections of human brain (occipital cortex)
Neutralization
Measured by its ability to neutralize TRAIL/TNFSF10-induced cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 2-8 ng/mL in the presence of 12 ng/mL Recombinant Human TRAIL/TNFSF10, a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody, and 1 µg/mL actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Cytotoxicity Induced by TRAIL/TNFSF10 and Neutralization by Human TRAIL/TNFSF10 Antibody. View Larger

Cytotoxicity Induced by TRAIL/TNFSF10 and Neutralization by Human TRAIL/TNFSF10 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induces cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, cytotoxicity elicited by Recombinant Human TRAIL/TNFSF10 (12 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL/TNFSF10 Monoclonal Antibody (Catalog # MAB375). The ND50 is typically 2-8 ng/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAIL/TNFSF10

TRAIL is a type II transmembrane protein belonging to the TNF superfamily and is now designated TNFSF10. TRAIL is active as a homotrimer and is produced by a variety of cell types in both the membrane bound form and also as a soluble molecule. It binds to any of the four TRAIL receptors as well as to Osteoprotegerin.

Long Name
TNF-related Apoptosis-inducing Ligand
Entrez Gene IDs
8743 (Human); 22035 (Mouse); 246775 (Rat)
Alternate Names
Apo-2 ligand; APO2L; Apo-2Ltumor necrosis factor (ligand) family, member 10; APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta; CD253 antigen; CD253; Protein TRAIL; TL2; TNF-related apoptosis-inducing ligand; TNFSF10; TRAIL; TRAILTNF-related apoptosis inducing ligand TRAIL; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor ligand superfamily member 10

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human TRAIL/TNFSF10 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

21 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
    Authors: AV Yagolovich, AA Isakova, AA Artykov, YV Vorontsova, DV Mazur, NV Antipova, MS Pavlyukov, MI Shakhparon, AM Gileva, EA Markvichev, EA Plotnikova, AA Pankratov, MP Kirpichnik, ME Gasparian, DA Dolgikh
    International Journal of Molecular Sciences, 2022-10-21;23(20):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Detection
  2. Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity
    Authors: AV Yagolovich, AA Artykov, AA Isakova, YV Vorontsova, DA Dolgikh, MP Kirpichnik, ME Gasparian
    International Journal of Molecular Sciences, 2022-05-24;23(11):.
    Species: Human
    Sample Types: Protein
    Applications: ELISA Capture
  3. Extracellular Vesicles: An Important Biomarker in Recurrent Pregnancy Loss?
    Authors: N Rajaratnam, NE Ditlevsen, JK Sloth, R Bæk, MM Jørgensen, OB Christians
    Journal of Clinical Medicine, 2021-06-09;10(12):.
    Species: Human
    Sample Types: Extracellular Vesicles
    Applications: IHC
  4. Improved Detection of HIV Gag p24 Protein Using a Combined Immunoprecipitation and Digital ELISA Method
    Authors: G Wu, C Cheney, Q Huang, DJ Hazuda, BJ Howell, P Zuck
    Frontiers in Microbiology, 2021-03-16;12(0):636703.
    Species: Human
    Sample Types: Tissue Lysates
    Applications: ELISA (Capture)
  5. Targeting triple-negative breast cancers with the Smac-mimetic birinapant
    Authors: N Lalaoui, D Merino, G Giner, F Vaillant, D Chau, L Liu, T Kratina, B Pal, JR Whittle, N Etemadi, J Berthelet, J Gräsel, C Hall, ME Ritchie, M Ernst, GK Smyth, DL Vaux, JE Visvader, GJ Lindeman, J Silke
    Cell Death Differ., 2020-04-27;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  6. Treatment with intravenous immunoglobulin increases the level of small EVs in plasma of pregnant women with recurrent pregnancy loss
    Authors: MM Jørgensen, R Bæk, J Sloth, K Varming, OB Christians, NE Ditlevsen, N Rajaratnam
    J. Reprod. Immunol., 2020-04-09;140(0):103128.
    Species: Human
    Sample Types: Plasma
    Applications: Bioassay
  7. A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
    Authors: ND Arnold, JA Pickworth, LE West, S Dawson, JA Carvalho, H Casbolt, AT Braithwait, J Iremonger, L Renshall, V Germaschew, M McCourt, P Bland-Ward, H Kowash, AG Hameed, AMK Rothman, MG Frid, AA Roger Thom, HR Evans, M Southwood, NW Morrell, DC Crossman, MKB Whyte, KR Stenmark, CM Newman, DG Kiely, SE Francis, A Lawrie
    Nat Commun, 2019-11-15;10(1):5183.
    Species: Mouse
    Sample Types: Whole Cell
    Applications: Neutralization
  8. Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNF alpha in Castration Resistant Prostate Cancer
    Authors: RE Vickman, J Yang, NA Lanman, GM Cresswell, F Zheng, C Zhang, RW Doerge, SA Crist, AD Mesecar, CD Hu, TL Ratliff
    Mol. Cancer Res., 2019-03-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  9. Combination of IAP antagonist and IFN? activates novel caspase-10- and RIPK1-dependent cell death pathways
    Authors: MC Tanzer, N Khan, JA Rickard, N Etemadi, N Lalaoui, SK Spall, JM Hildebrand, D Segal, M Miasari, D Chau, WL Wong, M McKinlay, SK Chunduru, CA Benetatos, SM Condon, JE Vince, MJ Herold, J Silke
    Cell Death Differ, 2017-01-20;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Negative control of TRAIL-R1 signaling by transforming growth factor ?1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1
    Cell Signal, 2016-08-01;28(11):1652-1662.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  11. Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment
    Authors: S V Singh, A K Ajay, N Mohammad, P Malvi, B Chaube, A S Meena et al.
    Cell Death & Disease
  12. A polysaccharide virulence factor of a human fungal pathogen induces neutrophil apoptosis via NK cells.
    Authors: Robinet P, Baychelier F, Fontaine T, Picard C, Debre P, Vieillard V, Latge J, Elbim C
    J Immunol, 2014-04-30;192(11):5332-42.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  13. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.
    Authors: Tel J, Smits E, Anguille S, Joshi R, Figdor C, de Vries I
    Blood, 2012-09-10;120(19):3936-44.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity.
    Authors: Kalb ML, Glaser A, Stary G, Koszik F, Stingl G
    J. Immunol., 2012-01-09;188(4):1583-91.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  15. TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN.
    Authors: Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP
    J. Interferon Cytokine Res., 2008-04-01;28(4):253-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  16. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor.
    Authors: Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR
    J. Biol. Chem., 2008-01-03;283(12):7754-62.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  17. Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
    Authors: Krysov SV, Krysov</LastName><ForeNam SV</Initia, Rowley TF, Al-Shamkhani A
    Mol. Cancer Ther., 2007-02-01;6(2):703-11.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  18. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.
    Authors: Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK
    Cell Death Differ., 2006-01-20;13(10):1789-801.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  19. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Authors: Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D
    J. Leukoc. Biol., 2005-06-03;78(2):359-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  20. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
    Authors: Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M
    Cancer Res., 2003-05-15;63(10):2369-72.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  21. High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability
    Authors: G Brunetti, A Di Benedet, F Posa, G Colaianni, MF Faienza, A Ballini, S Colucci, G Passeri, L Lo Muzio, M Grano, G Mori
    Oncol. Rep., 2018-02-15;0(0):.

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAIL/TNFSF10 Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL/TNFSF10 Antibody and earn rewards!

Have you used Human TRAIL/TNFSF10 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review